Metabolite Profiling of the Plasma and Leukocytes of Chronic Myeloid Leukemia Patients

详细信息    查看全文

• 作者：Radana Karlíková ; Jitka Široká ; David Friedecký ; Edgar Faber ; Marcela Hrdá ; Kateřina Mičová ; Iveta Fikarová ; Alžběta Gardlo ; Hana Janečková ; Ivo Vrobel ; Tomáš Adam
• 刊名：Journal of Proteome Research
• 出版年：2016
• 出版时间：September 2, 2016
• 年：2016
• 卷：15
• 期：9
• 页码：3158-3166
• 全文大小：477K
• 年卷期：0
• ISSN：1535-3907

文摘

The discovery of tyrosine kinase inhibitors (TKIs) brought a major breakthrough in the treatment of patients with chronic myeloid leukemia (CML). Pathogenetic CML events are closely linked with the Bcr-Abl protein with tyrosine kinase activity. TKIs block the ATP-binding site; therefore, the signal pathways leading to malignant transformation are no longer active. However, there is limited information about the impact of TKI treatment on the metabolome of CML patients. Using liquid chromatography mass spectrometric metabolite profiling and multivariate statistical methods, we analyzed plasma and leukocyte samples of patients newly diagnosed with CML, patients treated with hydroxyurea and TKIs (imatinib, dasatinib, nilotinib), and healthy controls. The global metabolic profiles clearly distinguished the newly diagnosed CML patients and the patients treated with hydroxyurea from those treated with TKIs and the healthy controls. The major changes were found in glycolysis, the citric acid cycle, and amino acid metabolism. We observed differences in the levels of amino acids and acylcarnitines between those patients responding to imatinib treatment and those who were resistant to it. According to our findings, the metabolic profiling may be potentially used as an additional tool for the assessment of response/resistance to imatinib.